Chongqing Precision Biotech

Company snapshot

Chongqing Precision Biotech maintains 109 tracked programs across Essential Tremor, Systemic Lupus Erythematosus, Focal Epilepsy, Multiple Myeloma, Colorectal Cancer, Major Depressive Disorder, Leukemia, B Cell Lymphoma, Gastric Cancer, Non-small Cell Lung Cancer, Glioblastoma Multiforme, Acute Lymphoblastic Leukemia, in Relapse. Momentum score: 20/100 (30-day delta: n/a). Public registry data cov

• 5 approved product(s) across US/EU regulatory metadata.
• 109 active pipeline program(s) linked via ClinicalTrials.gov.
• 158 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Chongqing Precision Biotech. Not investment advice.

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 50

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 40

• Peer + 0 momentum

  Merck KGaA, Darmstadt

  TA overlap score 32.6

• Peer + 0 momentum

  Nanjing Legend Biotech

  TA overlap score 27.2

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Samsung Bioepis

  TA overlap score 24.8

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Xenon Pharmaceuticals

  TA overlap score 24.4

Recent activity

Latest pipeline, patent, and corporate events for Chongqing Precision Biotech.

1. Jun 8, 2026 Clinical update

   PRAX-628-323 — Phase 3

2. Jun 8, 2026 Clinical update

   PRAX-628-322 — Phase 3

3. Jun 8, 2026 Clinical update

   PRAX-628-102 — Phase 1

4. Jun 8, 2026 Clinical update

   PBGENE-HBV-01 — Phase 1

5. Jun 8, 2026 Clinical update

   PB-2018-V12 — Phase 1

View all clinical trial activity →

• What is Chongqing Precision Biotech?

  Chongqing Precision Biotech is a biotech organization headquartered in Chongqing, CN. Primary therapeutic focus areas include Essential Tremor, Systemic Lupus Erythematosus, Focal Epilepsy, Multiple Myeloma, Colorectal Cancer. NovaPharmaNews links 109 clinical program(s), 5 drug

• Is Chongqing Precision Biotech publicly traded?

  Chongqing Precision Biotech appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chongqing Precision Biotech develop or market?

  We link 57 drug profile(s) where Chongqing Precision Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/precision-biosciences-inc#company-drugs.

• What are the latest developments for Chongqing Precision Biotech?

  In the last 12 months our linked public records show 109 trial program update(s) and 5 US patent grant(s) tied to this profile.

• What therapeutic areas does Chongqing Precision Biotech focus on?

  Chongqing Precision Biotech focuses on Essential Tremor, Systemic Lupus Erythematosus, Focal Epilepsy based on our analysis of their pipeline programs and drug development activities.